[A20-42] Brigatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 03.08.2020
Project no.:
A20-42
Commission:
Commission awarded on 29.04.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with ALK-positive advanced NSCLC who have not been previously treated with an ALK inhibitor
Patients with brain metastases at the start of treatment: indication of minor added benefit; patients without brain metastases at the start of treatment: hint of minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-08 | Brigatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-85 | Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42 | Commission completed |
| G20-21 | Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42 | Commission completed |